KRAS and lung cancer: Another mechanism of adaptation is found in defiance of MEK1/2 inhibitors, inhibitor‐treated colorectal, and lung cancer cell lines displayed intrachromosomal amplification of mutant Kras or BRAF or upregulation of upstream RTK signaling [80, 81].